Key facts
- PredxBio’s last known valuation is $24.5M (Jul 2025).
- It has raised $9.2M across 1 recorded rounds; the latest was Seed Round ($601K) in Aug 2023.
- Notable investors include US National Science Foundation, Keiretsu Forum, Innovation Works, UPMC Enterprises, Sacramento Angels — 14 tracked in total.
- PredxBio has filed 1 Form D with the SEC, most recently Aug 2023 ($601K sold to 11 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for PredxBio
Funding rounds
1 roundsAbout PredxBio
Operator of a software platform intended to transform complex tissue and biological data into decision-ready insights for biopharma and diagnostics organizations. The company's platform applies advanced spatial analytics and explainable AI (artificial intelligence) to interpret tissue architecture, cellular interactions, and biological context, enabling biopharma and diagnostics teams to support translational research, biomarker strategy, and clinical development with actionable evidence for program decisions.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2017
- Employees
- 7
- Website
- predxbio.com/
- Ownership
- Privately Held (backing)
PredxBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PredxBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PredxBio in its N-PORT filings yet. We sweep new filings monthly.